
Spectrum Pharmaceuticals Net Debt | SPPI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.9 M | -85.8 M | -43.6 M | -60.4 M | -157 M | -189 M | -61.2 M | -38.2 M | -33.6 M | -64.8 M | -64.7 M | -121 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.9 M | -189 M | -77.6 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Omeros Corporation
OMER
|
84 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
BioLineRx Ltd.
BLRX
|
-2.04 M | $ 0.94 | -10.44 % | $ 2.32 B | ||
|
PhaseBio Pharmaceuticals
PHAS
|
-39.4 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
-44.7 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
-19.9 M | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
202 M | - | - | $ 26.6 B | ||
|
Provention Bio
PRVB
|
-20.4 M | - | - | $ 2.37 B | ||
|
Reata Pharmaceuticals
RETA
|
77.2 M | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
-7.94 M | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
-137 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.46 M | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
-11 M | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
-59.7 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
-85.6 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
-141 M | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
-80.1 M | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
-1.16 M | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
-23.8 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
707 K | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
-4.58 M | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
-8.39 M | - | -24.84 % | $ 2.64 M | ||
|
CohBar
CWBR
|
-2.55 M | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
-52.4 M | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
122 M | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
-214 M | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
452 K | - | -48.37 % | $ 3.71 M | ||
|
Nabriva Therapeutics plc
NBRV
|
-7.19 M | - | - | $ 4.55 M | ||
|
Annovis Bio
ANVS
|
-8.07 M | $ 0.71 | -3.81 % | $ 14.6 M | ||
|
scPharmaceuticals
SCPH
|
-24.1 M | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
-51.9 M | - | - | $ 105 M | ||
|
Athersys
ATHX
|
-353 K | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
-433 M | - | - | $ 4.62 B | ||
|
Inozyme Pharma
INZY
|
11.3 M | - | - | $ 207 M | ||
|
NanoString Technologies
NSTG
|
120 M | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
-45 M | - | -81.12 % | $ 4.28 M | ||
|
CNS Pharmaceuticals
CNSP
|
-13.6 M | $ 3.56 | -9.07 % | $ 1.58 M | ||
|
Sorrento Therapeutics
SRNE
|
9.38 M | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
-20.5 M | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
-104 M | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
-1.36 M | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-7.95 M | - | -19.68 % | $ 18.4 M | ||
|
Jounce Therapeutics
JNCE
|
-141 M | - | - | $ 98.4 M | ||
|
Cocrystal Pharma
COCP
|
-5.52 M | $ 0.93 | -4.11 % | $ 10.5 M | ||
|
Fortress Biotech
FBIO
|
-24.8 M | $ 1.89 | 6.78 % | $ 52.7 M | ||
|
Acorda Therapeutics
ACOR
|
131 M | - | -24.86 % | $ 820 K | ||
|
Longeveron
LGVN
|
-3.84 M | $ 1.65 | -9.34 % | $ 29 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Immunic
IMUX
|
-14.9 M | $ 7.0 | -5.28 % | $ 1.09 B |